To include your compound in the COVID-19 Resource Center, submit it here.

Afyx: Mucosal drug delivery

How Afyx’s drug patches could replace topical agents for mucosal diseases

Afyx Therapeutics is developing bioadhesive patches for mucosal drug delivery to address diseases that are inadequately treated by topical agents.

Diseases affecting topically accessible mucosal sites, such as the buccal mucosa, are difficult to treat because mucosal secretions clear gel, cream and ointment formulations away from tissue, and adhesives generally do not stick well to wet surfaces.

Afyx’s Rivelin

Read the full 594 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE